A Phase 4, Study to Evaluate the Safety and Efficacy of Lesinurad 200 mg in Combination With a Xanthine Oxidase Inhibitor (XOI), Compared With an XOI Alone, in Subjects With Gout and Estimated Creatinine Clearance (eCrCl) 30 to <60 mL/Min Who Have Not Achieved Target Serum Uric Acid Levels (sUA) on an XOI Alone
Seeking subjects with Gout who have not met target Uric Acid levels on Xanthine Oxidase Inhibitor Alone.
Study Length: Up to 5 years
Target Age/Sex: 18-65, Male and Female
Participants will receive at no cost: Study medication, Study related lab work and medical exams. Subject will also receive a stipend for time/travel related to the study.